Ibrutinib Plus Venetoclax for First-Line Chronic Lymphocytic Leukemia Treatment

  • Wierda, William G. M.D., Ph.D.

  • 1 Division of Cancer Medicine, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston

Dr. Wierda can be contacted at [email protected] or at Division of Cancer Medicine, Department of Leukemia, University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd., FC4.2026, Houston, TX 77030.

NEJM Evidence 1(7), July 28, 2022. | DOI: 10.1056/EVIDe2200093

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

  • Kater, Arnon P. M.D., Ph.D.
  • Owen, Carolyn M.D.
  • Moreno, Carol M.D.
  • Follows, George B.M.Bch., Ph.D.
  • Munir, Talha M.B.B.S.
  • Levin, Mark-David M.D.
  • Benjamini, Ohad M.D.
  • Janssens, Ann M.D., Ph.D.
  • Osterborg, Anders M.D., Ph.D.
  • Robak, Tadeusz M.D., Ph.D.
  • Simkovic, Martin M.D., Ph.D.
  • Stevens, Don M.D.
  • Voloshin, Sergey M.D., Ph.D.
  • Vorobyev, Vladimir Ph.D.
  • Ysebaert, Loic M.D., Ph.D.
  • Qin, Rui Ph.D.
  • Steele, Andrew J. Ph.D.
  • Schuier, Natasha M.D.
  • Baeten, Kurt Ph.D.
  • Caces, Donne Bennett M.D., Ph.D.
  • Niemann, Carsten U. M.D., Ph.D.
NEJM Evidence 1(7), July 28, 2022. | DOI: 10.1056/EVIDoa2200006
Copyright © 2022 Massachusetts Medical Society. All rights reserved.
View full text|Download PDF